Friday, 23 Mar 2018

You are here

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.

  1. Study of 16207 RA patients >65yrs shows non-serious infection rate of 47.5/100PY; increased 20% by steroid use.Infx common in RA
  2. Rules for Drug Cessation with Infection 
  3. 241 patients with Clinically suspect arthralgia - Positive Serology increases RA risk: CCP HR 8.5; RF 5.1; CarbP Ab 3.9; RF+CCP+ has PPV 67%
  4. Frequence of Secondary Sjogrens is 20% in RA and 14% in SLE - with a >15 to 1 female to male ratio
  5. Lower RA dz activity & remission assoc w/ lower serious infection rates! Inflammation (not drugs) drives infx risk
  6. 107 JIA pts followed for 3 yrs on Biologics- 25% (35) had Serious/Opportunistic infx. range 10.6-14.8/100py
  7. In 19 RCTs, 6194 RA pts received tofacitinib for 19406 pt-Yrs & 19 developed lymphoma (SIR 2.62) or 1:1000 PY risk
  8. 2016 US Top selling drugs: Humira $13.6 billion, Enbrel $7.4 billion, Remicade $5.3 billion, Lyrica $4.4B,RTX $3.9B
  9. Idiopathic arthralgias pts with no US synovitis have negative predictive value 89% for developing inflam arthritis
  10. RA RCT Inclusion of FM or Depression pts or pts on SSRI had 10% less ACR20 & 1/2 LDAS responses, more W/D & AE
  11. In 7-15% PSA precedes Pso;In remainder, median time from PSO dx to PsA is 7-8yrs. <75% get PsA w/in 10-15 yrs of PsO
  12. IBD Associated with Increased risk of Autoimmune and Inflammatory Diseases
  13. Patterns of Biologic Use During Autoimmune Pregnancy 
  14. Alcohol Related Deaths Increased in Psoriasis



The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 23 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.

MMWR: Arthritis Prevalence Increases and Varies Widely

MMWR reports that In 2015, the number of adults with arthritis continued to increase; with marked geographic variability in arthritis estimates with gaps in arthritis management.

The CDC estimates that physician-diagnosed arthritis affects 54 million of adults in the United States with an annual cost of approximately $300 billion annually.

The RheumNow Week in Review - 16 March 2018

Dr. Jack Cush reviews the highlights from the news, journals and major meetings. Bigtime rheumatologic lessons with tales from intestinal crypts, the friendly skies & the hips of hockey players. Also the microbiome and lupus, benefits of ENT findings with GPA and rare risk of opportunistic infections with biologics.

The RheumNow Week in Review - 9 March 2018

Dr. Jack Cush reviews highlights, news and recent research published this past week on This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.

ACR Responds to Association Health Plans Proposed Rule

In comments submitted today to the US Department of Labor in response to its Association Health Plans (AHP) proposed rule, the American College of Rheumatology urged Administration officials to protect essential health benefits and other consumer protections that make it possible for individuals living with rheumatic diseases to access comprehensive and affordable healthcare.